Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells
暂无分享,去创建一个
U. Ikeda | K. Shimada | Keiji Yamamoto | M. Shimpo | R. Ohki | M. Takahashi | Hideko Inaba
[1] A. Michael,et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. , 2003, British journal of clinical pharmacology.
[2] F. Bernini,et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[3] R. Roman,et al. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. , 1998, American journal of hypertension.
[4] A. Henney,et al. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. , 1998, Clinical science.
[5] O. Eickelberg,et al. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. , 1997, International journal of cardiology.
[6] J. Pickering,et al. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[7] S. Sebti,et al. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity , 1997, Oncogene.
[8] Y. Kusumi,et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. , 1996, European journal of pharmacology.
[9] S. Shapiro,et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Ferguson,et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.
[11] F. Bernini,et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1995, The American journal of cardiology.
[12] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[13] U. Ikeda,et al. Suppressive role of endogenous endothelial monocyte chemoattractant protein-1 on monocyte transendothelial migration in vitro. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[14] KazuyukiShimada,et al. Suppressive Role of Endogenous Endothelial Monocyte Chemoattractant Protein–1 on Monocyte Transendothelial Migration In Vitro , 1995 .
[15] S. Yap,et al. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. , 1995, Biochimica et biophysica acta.
[16] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[17] E. Lakatta,et al. Increased expression of 72 kDa type IV collagenase (MMP-2) in human atherosclerotic lesions , 1994 .
[18] M. Rekhter,et al. Cell proliferation and collagen synthesis are two independent events in human atherosclerotic plaques. , 1994, Journal of vascular research.
[19] P. Libby,et al. Enhanced Expression of Vascular Matrix Metalloproteinases Induced In Vitro by Cytokines and in Regions of Human Atherosclerotic Lesions a , 1994, Annals of the New York Academy of Sciences.
[20] P. Heinrich,et al. Regulation of tissue inhibitor of metalloproteinases‐1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures , 1993, Hepatology.
[21] F. Bernini,et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. , 1993, Atherosclerosis.
[22] M A Schork,et al. Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. , 1993, The American journal of pathology.
[23] G. Gabbiani,et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. , 1993, Atherosclerosis.
[24] E. Donetti,et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[25] F. Tse,et al. Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.
[26] E. Lakatta,et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. , 1996, The American journal of pathology.
[27] D H Blankenhorn,et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1992, Circulation.
[28] S. Glagov,et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.